



Supporting first-line immunotherapy selection for metastatic NSCLC. PROphet® reveals clinical insights that equip oncologists to deliver more informed, personalized, data-driven treatment decisions.


PD-L1 ≥50% (n=213)




Takeaway: Durable benefit from PD-(L)1 inhibitors alone. No statistically significant difference in mOS with the addition of chemotherapy.




Takeaway: Statistically different OS despite getting the same treatment




Takeaway: Durable benefit from PD-(L)1 inhibitors + chemo combination




Takeaway: Low to moderate benefit from PD-(L)1 inhibitors + chemo combination




Takeaway: Statistically different OS despite getting the same treatment



Takeaway: Despite being PD-L1 negative there is still a durable benefit from PD-(L)1 inhibitors combined with chemotherapy



Takeaway: Poor OS with both treatments. Consider using other approved therapies or a 1st line clinical trial



Takeaway: Statistically different OS despite getting the same treatment



ORDER ONLINE: www.oncohost.com
CALL US: 855-950-2112 or **EMAIL:** contact@oncohost.com

OncoHost Inc. | 1110 SE Cary Parkway | Suite 205 | Cary, NC 27518 | CLIA ID Number: 34D2250951 | Terms of Use: oncohost.com/terms-of-use
Disclaimer: Testing is performed by OncoHost's CLIA-certified laboratory located in the USA. The PROphet test was developed, and its performance characteristics were determined by OncoHost LTD.

First-line treatment options for metastatic NSCLC with no actionable alterations

Regimens	PD-L1 ≥ 50%	PD-L1 1-49%	PD-L1 <1%	
Pembrolizumab Keynote 024, Keynote 042				NCCN ASCO
Atezolizumab IMpower 110				NCCN ASCO
Cemiplimab EMPOWER -lung 1				NCCN ASCO
Pembrolizumab + chemotherapy Keynote 189, Keynote 407				NCCN ASCO
Cemiplimab + chemotherapy EMPOWER -lung 3				NCCN ASCO
Atezolizumab + chemotherapy* IMpower 130				NCCN ASCO
Nivolumab + ipilimumab + chemotherapy Checkmate 9LA				NCCN ASCO
Durvalumab + tremelimumab + chemotherapy Poseidon				NCCN ASCO
Atezolizumab + bevacizumab + chemotherapy* IMpower 150				NCCN ASCO
Nivolumab + ipilimumab Checkmate 227				NCCN ASCO

- Preferred / Strong recommendation
- Other recommended / Moderate recommendation
- Not recommended/certain circumstances / Weak recommendation

*Non-squamous only

Treatments are categorized based on clinical guidelines provided by the National Comprehensive Cancer Network (NCCN, [Non-Small Cell Lung Cancer 3.2025](#)) and the American Society of Clinical Oncology (ASCO, [version 2023.3](#)).

If the strength of recommendation varied between histology the non-squamous strength was reported. Strengths of recommendation also assumed optimal chemotherapy backbone for histology.

Modified from [Wang et al Nature Reviews Clinical Cancer 2025](#).